Vor Biopharma (NYSE:VOR) Trading Down 5.3%

Vor Biopharma Inc. (NYSE:VOR)’s share price traded down 5.3% on Monday . The company traded as low as $1.76 and last traded at $1.80. 295,895 shares were traded during mid-day trading, a decline of 1% from the average session volume of 299,641 shares. The stock had previously closed at $1.90.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. Stifel Nicolaus reduced their price target on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma has a consensus rating of “Buy” and a consensus price target of $13.50.

Vor Biopharma Price Performance

The business’s 50 day moving average is $2.09 and its 200 day moving average is $2.12. The stock has a market cap of $122.80 million, a price-to-earnings ratio of -1.02 and a beta of -0.36.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.10. As a group, analysts forecast that Vor Biopharma Inc. will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its holdings in Vor Biopharma by 132.0% during the fourth quarter. Bank of America Corp DE now owns 3,942 shares of the company’s stock worth $26,000 after purchasing an additional 2,243 shares in the last quarter. UBS Group AG purchased a new position in Vor Biopharma during the fourth quarter worth about $27,000. Jane Street Group LLC purchased a new position in Vor Biopharma during the third quarter worth about $41,000. State Board of Administration of Florida Retirement System purchased a new position in Vor Biopharma during the second quarter worth about $33,000. Finally, Virtu Financial LLC purchased a new position in Vor Biopharma during the second quarter worth about $61,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.